Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
US RESEARCHERS: BIRD FLU VACCINE EFFECT ON HUMANS

Bird flu vaccine may work in humans: US researchers

 

BY OUR PHARMA  CORRESPONDENT

8 August, 2005: Researcher of the National Institute of Allergy and Infectious Diseases in the United States claim that a vaccine developed against avian influenza could be useful in humans.

The vaccine is yet to undergo preliminary tests in humans, still the government researchers expressed the optimism that it can be used on an emergency basis if a pandemic developed.

Additional tests are needed to determine the number of vaccine shots required for protection, optimal dose of vaccine; and whether adding another ingredient to the vaccine could raise the potency of lower doses. Even when these tests are completed, more time will be needed before the Food and Drug Administration can license the human vaccine.

The National Institute of Allergy and Infectious Diseases scientists said that tests so far had shown that the new vaccine produced a strong immune response among the small group of healthy adults under age 65 who volunteered to receive it, although the doses needed were higher than in the standard influenza vaccine offered each year. The vaccine, developed with genetic engineering techniques, is intended to protect against infection, not to treat those who are sick.

Further tests are expected to be conducted among two groups - people 65 and older, and children - over the next several months.

However, they maintained that mass production of such a vaccine could well pose problems because the vaccine is made in chicken eggs. It all depends upon the number of eggs farmers can supply manufacturers. If manufacturers can overcome such hurdles, the new vaccine could go far in averting a possible pandemic of human influenza.

Health experts world over have been trying to develop a vaccine against the diseases because they a fear a pandemic as a strain of avian influenza is spreading in birds through Asia and Russia. Tens of millions of birds have died from the infection. Nearly 100 people have been infected, and about 50 have died from this strain of the avian influenza virus, called A(H5N1).

Earlier, a human vaccine against the A(H5N1) avian influenza virus was prepared after it first appeared in the world, in Hong Kong in 1997. That vaccine was never fully developed or used, and the strain has mutated since then.

So far, only a small number of human cases of A(H5N1) influenza have been found. Although a few cases may have been transmitted from person to person in Asia, the A(H5N1) strain has not garnered enough strength to spread widely among humans anywhere.

According to the World Health Organization in Geneva, the avian strain has killed 57 of the 112 people it has been known to infect in four countries. They are Cambodia (4 cases), Indonesia (one case), Thailand (17 cases) and Vietnam (90 cases).

The United States is thought to be the only country that has produced a human vaccine against the A(H5N1) influenza strain. Australia, Canada, France and Japan are among countries where scientists are trying to develop an effective vaccine.

Government researchers in the US developed the vaccine, which is produced by Sanofi-Pasteur, a French vaccine company that is now part of Aventis.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

More funding for Sentinel Breastscan

New drug Provigil can keep you awake: Cephalon

Anti-virals can stem global flu outbreak: Studies

USFDA’s recall overdrive creates panic among drug users

Backjoy - A chair support that helps relieve back pain

Why does mammography lead to pain for some black women?

What after the Atkins diet?

Perrigo recalls infants’ oral drops in US

Diovan approved to treat heart failure in US

British Pharma seeks opinion on industry code

Novartis gets EU nod for Xolair

Eli Lilly to submit ruboxistaurin for diabetic vision loss

Snuppy: The first cloned dog

India bans valdecoxib

UK recalls Lipitor fakes

Drug developers set sight on 'interactome'

Ranbaxy gets US FDA nod for sumatriptan tabs

US FDA approval for Orchid's ceftriaxone vials

Pfizer's Celebrex approved for spondilitis

IVAX gets FDA okay for hydrochlorothiazide caps

Mumbai floods: Pharma sector losses estimated at Rs 1,000 crore

Calorie Control Council Statement: Allegations Against Aspartame Unfounded

European biotech start-ups fail to win late-stage funds

Ranbaxy gets USFDA nod for glimepiride tabs

Experts debate benefits of heart implant in US

US FDA blocks sale of Pharmakon's illegal drugs

Echinacea does not prevent common cold: Study

Afghan’s first generics plant to go on stream by Oct. ‘05

PhRMA seeks voluntary DTC ad code

Barr, Teva get fexofenadine approvals from US FDA

Novartis completes Eon Labs buy

Able Laboratories files bankruptcy suit with US court

Orbus inks supply pact with Docpharma 

Matrix acquires controlling stake in Docpharma

Actavis launches Fosinopril in Netherlands, Sweden &UK; Benazepril in Germany

Insomnia treatment: ROZEREM approved by FDA

Stories below archived on 25 July, 2005

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us